Background
Microbiology
- Single-stranded negative-sense RNA virus in the Retroviridae family, genus Deltaretrovirus
- Four types:
- HTLV-1, cause of adult T-cell leukemia-lymphoma and HTLV-associated myelopathy
- HTLV-2, cause of HTLV-associated myelopathy
- HTLV-3 and HTLV-4 are rare
Epidemiology
- HTLV-1 endemic to central Africa, the Caribbean basin, parts of South America, and southwestern Japan
- HTLV-2 endemic to indigenous people in the Americas, and Central African pygmies, as well as injection drug users in North America and Europe
- Transmitted sexually, parenterally (blood-borne), and vertically (mother-to-child, primarily through breastfeeding)
- Seroprevalence increases with age and is higher in women than men
Clinical Manifestations
Syndrome | HTLV-1 | HTLV-2 |
---|---|---|
Children | ||
Infective dermatitis | yes | no |
Lymphadenopathy | yes | yes |
Adults | ||
Adult T-cell leukemia-lymphoma | yes | no |
HTLV-associated myelopathy | yes | yes |
Infective dermatitis | yes | no |
Polymyositis | possibly | unknown |
Uveitis | yes | unknown |
HTLV-associated arthritis | possibly | possibly |
Sjögren syndrome | possibly | unknown |
Strongyloidiasis | possibly | unknown |
Pulmonary infiltrative pneumonitis | possibly | possibly |
Invasive cervical cancer | possibly | unknown |
Adult T-cell Leukemia-Lymphoma (ATL)
- Associated with HTLV-1, with a lifetime risk of 2 to 4% and latent period to 30 to 50 years
- Aggressive T-cell leukemia or lymphoma with four subtypes
- Smoldering (5%), with ≥5% abnormal T-cells but otherwise normal differential, ± skin lesions ± pulmonary involvement
- Chronic (19%), with lymphocytosis ≥4 and T-cells >3.5, ± lymphadenopathy/organomegaly/skin lesions/pulmonary involvement
- Lymphoma/leukemia (19%), with lymphadenopathy without lymphocytosis; poor prognosis (median 10 months)
- Acute (57%), with increased leukemic T cells and worsening clinical picture including hypercalcemia; poor prognosis (median 6 months)
- Presents with lymphadenopathy, hepatosplenomegaly, hypercalcemia, skin lesions, lytic bone lesions, and abnormal peripheral blood film with lymphocytosis and "flower cells"
- Skin findings can be either localized or diffuse as papules, nodules, plaques, erythematous patches, and diffuse erythroderma
HTLV-Associated Myelopathy
- Also called tropical spastic paraparesis
- Associated with HTLV-1 and -2, with lifetime prevalence of 4%
- Thought to be caused by an autoimmune response from HTLV-1 antibodies due to molecular mimicry
- Chronic progressive demyelinating disease affecting white matter and spinal cord
- Unexplained central neurological disease with loss of pyramidal tract
- Stiff gait progressing to spasticity and weakness, back pain, urinary incontinence, and impotence
- Can have parasthesias and burning sensation
- Impaired vibration sense
- Hyperreflexia with clonus and upgoing plantar reflexes
- Usually insidious onset, but can be acute
- MRI may be normal or show atrophy of the spinal cord and non-specific brain lesions
- CSF can have mild lymphocytosis and mild protein elevation, including oligoclonal bands
Other Syndromes
HTLV-1
- Other neurological abnormalities, including sensory neuropathy, gait abnormality, bladder dysfunction, erectile dysfunction, amyotrophic lateral sclerosis, mild cognitive deficit, and motor neuropathy
- Infective dermatitis, which occurs in children who experience failure to thrive, eczema, and Gram-positive infections
- Polymyositis (HTLV-1-associated inflammatory myopathy of skeletal muscle)
- Large joint polyarthropathy
- Uveitis
- Infiltrative pneumonitis
- Chronic lympadenopathy
- Increased infections:
- Strongyloides hyperinfection
- Crusted scabies
- Pneumocystis jirovecii
- Mycobacterium avium complex
HTLV-2
- Rarely, HAM and other neurological abnormalities
Differential Diagnosis
HTLV-Associated Myelopathy
- Multiple sclerosis, which should have a more waxing-waning course
- Spinal cord tumour
- Toxic neuropathy
- Malnutrition
- HIV
- Syphilis
Management
- Monitoring for signs or symptoms of leukemia, lymphoma, and neurological disease
- Management of ATL per Hematologi-Oncology service